← Leaderboards
Yong Wan
Emory University
$11,312,987
Attributed
$12,563,644
Total exposure
8
Grants
8
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.9M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,563,644 · 8
By mechanism
R01$12,161,376 · 7
R21$402,268 · 1
Top collaborators
- Bin Zhang5 shared
Most similar at Emory University
Same institution · by research overlap
- Shi-Yong Sun$12,583,440
- Wolfram Siede$1,853,450
- Samuel C Dudley$19,023,025
- Amr Ghaleb$171,954
- Xiao-Jiang Li$16,112,155
Others in their field
Top investigators on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Lawrence Corey · Fred Hutchinson Cancer Center$493,822,581
- Barton F Haynes · Duke University$295,802,493
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$286,700,869
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$176,977,598
- Dan H. Barouch · Fred Hutchinson Cancer Center$122,734,499
Research focus
MediatingMolecularMammary NeoplasmsIn VivoTumor ProgressionSignal TransductionCellsMalignant Breast NeoplasmUbiquitin-Protein LigaseOncogenicBreast CarcinogenesisClinically RelevantThe Cancer Genome AtlasCarcinogenesisResponsePathologicTherapeutic InterventionTumorigenesisMouse ModelTumorBreast Cancer TherapyPost-Translational Protein ProcessingBreast Cancer CellProtein Complex
Grant awards (40)
Targeting posttranslational modifications of CD73 in TNBCs$644,746
R01 · FY2025 · CA · contact PI
Targeting posttranslational modifications of B7-H4 in carcinogenesis and therapy$503,234
R01 · FY2025 · CA · contact PI
Targeting Posttranslational Modifications in Breast Carcinogenesis$455,680
R01 · FY2025 · CA · contact PI
Targeting posttranslational modifications of CD73 in TNBCs$533,393
R01 · FY2024 · CA · contact PI
Targeting posttranslational modifications of B7-H4 in carcinogenesis and therapy$471,315
R01 · FY2024 · CA · contact PI
Targeting Posttranslational Modifications in Breast Carcinogenesis$427,217
R01 · FY2024 · CA · contact PI
Targeting posttranslational modifications of B7-H4 in carcinogenesis and therapy$1
R01 · FY2023 · CA · contact PI
Targeting Posttranslational Modifications in Breast Carcinogenesis$1
R01 · FY2023 · CA · contact PI
Targeting posttranslational modifications of CD73 in TNBCs$1
R01 · FY2023 · CA · contact PI
Targeting posttranslational modifications of CD73 in TNBCs$663,953
R01 · FY2022 · CA · contact PI
Targeting posttranslational modifications of B7-H4 in carcinogenesis and therapy$518,180
R01 · FY2022 · CA · contact PI
Targeting Posttranslational Modifications in Breast Carcinogenesis$462,243
R01 · FY2022 · CA · contact PI
Targeting posttranslational modifications of CD73 in TNBCs$659,221
R01 · FY2021 · CA · contact PI
Targeting posttranslational modifications of B7-H4 in carcinogenesis and therapy$522,459
R01 · FY2021 · CA · contact PI
Targeting Posttranslational Modifications in Breast Carcinogenesis$474,218
R01 · FY2021 · CA · contact PI
Interplay between ER and TGF-b in carcinogenesis$172,997
R01 · FY2021 · CA · contact PI
Interplay between ER and TGF-b in carcinogenesis$81,170
R01 · FY2021 · CA · contact PI
Targeting Posttranslational Modifications in Breast Carcinogenesis$461,234
R01 · FY2020 · CA · contact PI
Interplay between ER and TGF-b in carcinogenesis$254,167
R01 · FY2020 · CA · contact PI
Targeting interplay between KLF4 and PRMT5 in carcinogenesis$253,214
R01 · FY2020 · CA · contact PI
Targeting interplay between KLF4 and PRMT5 in carcinogenesis$245,617
R01 · FY2019 · CA · contact PI
Interplay between ER and TGF-b in carcinogenesis$121,983
R01 · FY2019 · CA · contact PI
Targeting interplay between KLF4 and PRMT5 in carcinogenesis$123,815
R01 · FY2018 · CA · contact PI
Interplay between ER and TGF-b in carcinogenesis$261,090
R01 · FY2017 · CA · contact PI
Targeting interplay between KLF4 and PRMT5 in carcinogenesis$259,934
R01 · FY2017 · CA · contact PI
Interplay between ER and TGF-b in carcinogenesis$124,558
R01 · FY2017 · CA · contact PI
Interplay between ER and TGF-b in carcinogenesis$381,991
R01 · FY2016 · CA · contact PI
Targeting interplay between KLF4 and PRMT5 in carcinogenesis$380,585
R01 · FY2016 · CA · contact PI
Interplay between Cdh1/APC and Rad17 in DNA damage checkpoints and carcinogenesis$308,228
R01 · FY2015 · CA · contact PI
Interplay between Cdh1/APC and Rad17 in DNA damage checkpoints and carcinogenesis$299,155
R01 · FY2014 · CA · contact PI
Interplay between Cdh1/APC and Rad17 in DNA damage checkpoints and carcinogenesis$290,066
R01 · FY2013 · CA · contact PI
Interplay between Cdh1/APC and Rad17 in DNA damage checkpoints and carcinogenesis$301,910
R01 · FY2012 · CA · contact PI
Interplay between Cdh1/APC and Rad17 in DNA damage checkpoints and carcinogenesis$304,638
R01 · FY2011 · CA · contact PI
Activation of APC by TGF-beta Suppresses Breast Cancer$290,472
R01 · FY2009 · CA · contact PI
Activation of APC by TGF-beta Suppresses Breast Cancer$222,472
R01 · FY2008 · CA · contact PI
Activation of APC by TGF-beta Suppresses Breast Cancer$222,472
R01 · FY2007 · CA · contact PI
UBIQUITIN-MEDIATED CIRCUITRY IN GENOMIC INTEGRITY$253,768
R21 · FY2006 · GM · contact PI
Activation of APC by TGF-beta Suppresses Breast Cancer$229,116
R01 · FY2006 · CA · contact PI
Activation of APC by TGF-beta Suppresses Breast Cancer$234,630
R01 · FY2005 · CA
UBIQUITIN-MEDIATED CIRCUITRY IN GENOMIC INTEGRITY$148,500
R21 · FY2005 · GM